Andere talen Perspective Therapeutics, Inc.

Aandelen

CATX

US46489V3024

Vertraagde tijd Nyse Andere beurzen 22:00:00 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,93 ^USD	+15,38%		-5,32%	+196,77%

12/06	Sectorupdate: Gezondheidszorgaandelen dalen aan het eind van de middag	MT
12/06	Sectorupdate: Aandelen gezondheidszorg woensdagmiddag zachter	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Sector Update: Health Care Stocks Ease Late Afternoon	12/06
Sector Update: Health Care Stocks Softer Wednesday Afternoon	12/06
Perspective Therapeutics to Join Russell 3000 Index on July 1	12/06
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index	12/06
Perspective Therapeutics to Reverse Split Common Shares	11/06
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split	11/06
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split	11/06
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	10/06
Perspective Therapeutics Prices $80 Million Share, Warrant Offering	24/05
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	24/05
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024	21/05
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024	20/05
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	15/05
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results	15/05
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Perspective Therapeutics to Participate at Upcoming May Investor Conferences	06/05
Perspective Therapeutics to Participate at Upcoming May Investor Conferences	03/05
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results	02/05
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30/04
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Perspective Therapeutics, Inc.

Aandelen

CATX

US46489V3024

Andere talen

Filters